Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioceres Crop Solutions (BIOX) Cash & Current Investments (2016 - 2026)

Bioceres Crop Solutions' Cash & Current Investments history spans 11 years, with the latest figure at $13.9 million for Q1 2026.

  • On a quarterly basis, Cash & Current Investments rose 135.28% to $13.9 million in Q1 2026 year-over-year; TTM through Mar 2026 was $13.9 million, a 135.28% increase, with the full-year FY2025 number at $45.9 million, down 28.24% from a year prior.
  • Cash & Current Investments hit $13.9 million in Q1 2026 for Bioceres Crop Solutions, down from $45.9 million in the prior quarter.
  • Over the last five years, Cash & Current Investments for BIOX hit a ceiling of $64.0 million in Q2 2024 and a floor of -$39.4 million in Q1 2025.
  • Historically, Cash & Current Investments has averaged $30.6 million across 5 years, with a median of $42.4 million in 2022.
  • Biggest five-year swings in Cash & Current Investments: fell 28.24% in 2025 and later soared 135.28% in 2026.
  • Tracing BIOX's Cash & Current Investments over 5 years: stood at $38.9 million in 2022, then skyrocketed by 55.01% to $60.3 million in 2023, then rose by 6.16% to $64.0 million in 2024, then dropped by 28.24% to $45.9 million in 2025, then plummeted by 69.72% to $13.9 million in 2026.
  • Business Quant data shows Cash & Current Investments for BIOX at $13.9 million in Q1 2026, $45.9 million in Q2 2025, and -$39.4 million in Q1 2025.